Biogen discusses Avonex trial

Biogen’s Avonex (interferon beta-1a) is effective in treating patients who experience their first episode of multiple sclerosis, it has claimed.

Data from the Champions ten-year follow up study showed sufferers who were treated as soon as they encountered the disease were less likely to undergo a second attack compared to those who received delayed therapy.

Investigations also revealed some 80 per cent of patients taking the drug scored an expanded disability status scale of below three.

Dr R Philip Kinkel, lead scientist of the study, said the results confirm that high risk patients could reduce disease progression for up to a decade if they are treated shortly after symptoms begin.

“This may translate into an ability to remain active and enjoy daily activities that otherwise might be lost without treatment,” he noted.

Dr Thorsten Eickenhorst, vice-president of global medical affairs at Biogen, added the data from the trials reinforce the effectiveness of Avonex.

Earlier this month, the company released its 2009 first quarter results. The company’s president and chief executive officer James C Mullen explained all three marketed products had achieved revenue growth.